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by Hugo Koch, Division of Health Care Statistics 
The relationship between the age and sex of am­
bulatory patients and the drugs ordered or provided 
for them by physicians in office-based practice is ex­
plored. Data are presented using fiidings from the 
1980 National Ambulatory Medical Care Survey. 
The National Center for Health Statistics uses the 
National Ambulatory Medical Care Survey (NAMCS) 
to collect descriptive data about the medical care pro­
vided in doctors’ offices. Each year NAMCS data col­
lectors contact a representative sample of the 
Nation’s doctors of medicine and osteopathy whose 
primary jobs are office-based, patient-care practice. 
The sampled physicians in turn complete records (fig­
ure 1) for a systematic random sample of their office 
visits over a weekly reporting period. When the sam­
pled findings were expanded to approximate the en-
tire universe of office-based care, the result was an 
estimated total of 575,745,000 office visits in calen­
dar 1980. 
The year 1980 was the fmt in the 8-year history 
of NAMCS that respondents reported the number and 
names of the specific drugs they used. (See figure 1, 
item 11.) This resulted in an estimated 679,593,000 
mentions of pharmaceutical agents ordered or pro­
vided–by any route of administration-for the pur­
pose of prevention, diagnosis, or treatment. Mentions 
included new or continued medications and nonpre­
scription as well as prescription drugs. The method­
ology used to collect, classify, and process drug infor­
mation for the 1980 NAMCS is reported elsewhere.1 
lNation~ centerfor He~th Statistics, H. Koch: The collection and 
processing of drug information, National Ambulatory Medical Care 
Survey, United States, 1980. Vital and Health Statistics. Series 2-No. 
90. DHHS pub. No. (PHS) 82-1364. Public Health Service. Washington. 
U.S. Government Printing Office. In press. 
Actual findings of drug utilization for the year have 
appeared in two prior publications.zj 3 
Since the estimates presented in this report are 
based on a sample rather than on the entire universe 
of office visits, the data are subject to sampling vari­
ability. The technical notes at the end of the report 
provide a brief explanation of sampling errors, and 
guidelines for judging the precision of estimates. 
General patterns of drug utilization 
Drug utilization may be viewed from differing 
perspectives and measured in differing ways, depend­
ing on the needs of the data user (table 1). Three 
evaluative terms require clarification at the outset. 
�	 A drug visit is an office visit at which one or more 
drugs are ordered or provided. In 1980 there were 
an estimated 363.5 million drug visits, comprising 
63 percent of the total 575.7 million office visits. 
.	 The drug mention rate is the average number of 
drugs utilized per office visit, obtained by dividing 
the number of office visits into the number of 
drug mentions. For the entire universe of 575.7 
million office visits, the overall drug mention rate 
was 1.18 drugs per average office visit. 
2Nati~n~ center for He~fi Statktics, T. McL,emore and H. Koch: 
1980 Summary, National Ambulatory Medical Care Survey. Advance 
Data From Vital and Health Statistics, No. 77. DHHS Pub. No. (PHS) 
82-1250. Public Health Service. Hyattsville, Md. Feb. 22,1982. 
3Natio~ Center for H~fi Stattiics, H. Koch: Drugs most frequently 
used in office-based practice, National Ambulatory Medical Care Sur­
vey, United States, 1980. Advance Data From Vital and Health Sta­
tistics, No. 78. DHHS Pub. No. (PHS) 82-1250. Pnblic Health Service. 
Hyattsville, Md. In preparation. 
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Figure 1. Patient Record from the National Ambulatory Medical Care Survey 
�	 The drug intensity rate is the average number of 
drugs utilized per drug visit, obtained by dividing 
the number of drug visits into the number of drug 
mentions. For the entire 363.5 million drug visits, 
the rate was 1.87 drugs per average drug visit. 
If simple volume of utilization is the desired 
criterion, then–depending on the degree of precision 
required–the data user may count the number of 
drug visits or drug mentions. When this simple enu­
meration is applied to a study of sex differences, it 
becomes readily apparent that drug visits or mentions 
for female patients substantially outnumbered drug 
visits and mentions for males. The ratio of about 6 to 
4 in favor of female patients closely parallels the ratio 
for office visits in general. However, when drug utili­
zation by the sexes is explored from other perspec­
tives, especially those of average usage, a different 
picture emerges. Examine, for example, the respective 
proportions of all office visits represented by the drug 
visits. For female patients it was 63.3 percent, for 
males 62.8 percent. The difference between the two 
proportions is not statistically significant, since it 
could be due to sampling error or variability. In addi­
tion, there is no significant difference between the 
average female and male patient in terms of their re­
spective drug mention rates or drug intensity rates. 
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Table 1. Number and percent distribution of office visits and drug mentions, number of drug visits and their percent of office visits, drug mention 
rate, and drug intensity rate, by age and sex of the office patient: United States, 1980 
Office visits Drug visits~ Drug mentions 
Drug Dru.o 













thousands thousands thousands 
All patients . . . . . . . . . . . . . . . . . . 575,745 100.0 363,489 63.1 679,593 100.0 1.18 1.87 
Sex 
Female . . . . . . . . . . . . . . . . . . . . . 346,106 60.1 219,216 63.3 413,570 60.9 1.19 1.89 
Male . . . . . . . . . . . . . . . . . . . . . . 229,639 39.1 144,274 62.8 266,023 39.1 1.16 1.84 
Age 
Under15years . . . . . . . . . . . . . . . 109,356 19.0 71,763 65.6 115,643 17.0 1.06 1.61 
15-24years . . . . . . . . . . . . . . . . . . 81,561 14.2 46,353 56.8 75,213 11.1 0.92 1.62 
25-44years . . . . . . . . . . . . . . . . . . 154,695 26.9 87,343 56.5 148,126 21.8 0.96 1.70 
45-64years . . . . . . . . . . . . . . . . . . 129,645 22.5 86,327 66.6 175,572 25.8 1.35 2.03 
65yearsandover . . . . . . . . . . . . . . 100,488 17.5 71,704 71.4 165,038 24.3 1.64 2.30 
Sex and age 
Female 
Under15years . . . . . . . . . . . . . 50,503 8.8 33,395 66.1 54,723 8.1 1.08 1.64 
15-24years . . . . . . . . . . . . . . . . 54,879 9.5 31,350 57.1 49;823 7.3 0.91 1.59 
25-44years . . . . . . . . . . . . . . . . 103,562 18.0 58,025 56.0 97,947 14.4 0.95 1.69 
45-64years . . . . . . . . . . . . . . . . 76,385 13.3 52,223 68.4 106,333 15.6 1.39 2.04 
65yearsandover . . . . . . . . . . . . 60,777 10.6 44,222 72.8 104,745 15.4 1.72 2.37 
Male 
Under15years . . . . . . . . . . . . . 58,852 10.2 38,368 65.2 60,920 9.0 1.04 1.59 
15-24years . . . . . . . . . . . . . . . . 26,682 4.6 15,003 56.2 25,391 3.7 0.95 1.69 
25-44years . . . . . . . . . . . . . . . . 51,134 8.9 29,318 57.3 50,179 7.4 0.98 1.71 
45-64years . . . . . . . . . . . . . . . . 53,260 9.3 34,105 64.0 69,239 10.2 1.30 2.03 
65yearsand over . . . . . . . . . . . . 39,712 6.9 27,481 69.2 60,294 8.9 1.52 2.19 
‘An office visit at which one or more drugs were’ordered or provided. 
2Theaverage number of drugs orderod or provided Per Office visit. 
3The average number of drugs ordered or providedperdrugvisit.

The same measurements maybe applied to drug 
utilization by age groups. When the criterion is a 
simple number of drug visits ormentions, the volume 
of utilization is greatest in the middle years, diminish­
ing in the age interval over 64 years. However, apply­
ing the drug mention rate produces a different 
pattern, one showing that average utilization steadily 
increases after the 14th year, reaching its highest 
point in the age group 65 years and over (figure 2). 
For the sex-age groups (figure 3) the drug mention 
rates for female and male patients follow the general 
pattern shown in figure 2, pursuing closely parallel 
paths until they diverge for the age group 65 years 
and over where, at a rate of 1.72 drug mentions per 
office visit, drug utilization by female patients sig­
nificantly exceeds that for males (1.52). 
Drug utilization: therapeutic categories 
Table 2 measures drug utilization from another 
perspective. Here the differences between the sexes 
and the age groups are described in terms of the 
therapeutic effects that the drugs were intended to 
produce. For example, an examination of total usage 
(by all patients) shows the clear preeminence of men­
tion enjoyed by three therapeutic categories: anti-
infective agents, cardiovascular drugs, and central 
nervous system drugs. Together they accounted for 
41 percent of the total 679.6 million drug mentions. 
A comparison of the sexes reveals that: 
FemaIe patients exceeded male patients in the 
proportion of their drug mentions represented by 
the following therapeutic categories: 
� Antineoplastic agents. 
�	 Central nervous system drugs (here, the differ­
ence between the sexes was very slight). 
�	 Electrolytic, caloric, and water balance sub-
stances, e.g., diuretics (again, the sex differ­
ence was slight). 
� Hormones and synthetic substances. 
� Vitamins. 
Male patients exceeded female patients in the pro-
portion of their drug mentions represented by the 
following therapeutic categories: 
� Antihistamine drugs. 
� Anti-infective agents. 























Under 15-24 25-44 45-64 65 and Under 15-24 25-44 45-64 65 and 
15 over 15 over 
Age of patient Age of patient 
1Average““m&r of drugsordered or provided PerofficeVisit. 1Avera~ number of drugsordered or provided perofficevisit. 
Figure 2. Drug mention rate by age of patient: United States, 1980 Figure 3. Drug mention rate by sex and age of patient: United States, 
1980 
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Table 2. Percent distribution of drug mentions by therapeutic category, according to sex and age of the patient: United States, 1980 
Thempeutic categow’ 
All categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Antihistaminedrugs . . . . . . . . . . . . . . . . . . . . . . . . 
Anti-infectiveagents . . . . . . . . . . . . . . . . . . . . . . . 
Antibiotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Antineoplasticagents . . . . . . . . . . . . . . . . . . . . . . . 
Autonomicdrugs . . . . . . . . . . . . . . . . . . . . . . . . . . 
Blood formationandcoagulation . . . . . . . . . . . . . . . 
Cardiovasculardrugs . . . . . . . . . . . . . . . . . . . . . . . 
Cardiacdrugs . . . . . . . . . . . . . . . . . . . . . . . . . . 
Hypotensiveagents . . . . . . . . . . . . . . . . . . . . . . 
Vasodilatingagants . . . . . . . . . . . . . . . . . . . . . . 
Central nervoussystemdrugs. . . . . . . . . . . . . . . . . . 
Analgesicsandantipyretics . . . . . . . . . . . . . . . . . 
Psychotherapeuticagents . . . . . . . . . . . . . . . . . . 
Sedativesand hypnotics . . . . . . . . . . . . . . . . . . . 
Electrolytic,caloric, andwater balance . . . . . . . . . . . 
Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Expectorants andcough preparations . . . . . . . . . . . . 
Eye, ear, nose, andthroat preparations . . . . . . . . . . . 
Gastrointestinal drugs . . . . . . . . . . . . . . . . . . . . . . . 
Hormones and synthetic substances . . . . . . . . . . . . . 
Adrenals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Sarums,toxoids,andvaccines . . . . . . . . . . . . . . . . . 
Skinandmucous membrane preparations . . . . . . . . . . 
Spasmolyticagents . . . . . . . . . . . . . . . . . . . . . . . . 
Vitamins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Othertherapeuticcategories . . . . . . . . . . . . . . . . . . 
Unknown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Drug mentions 
Sex of patient Age of patient 
All 
patients Female Male Under 1524 






679,593 413.,570 266,023 115,643 75,213 148,126 175,572 165.038 
Percent distribution 
100.00 100.00 100,00 100.00 100.00 100.00 100.00 100.00 
6.47 5.64 7.28 14.60 7.75 7.16 3.90 2.29 
15.44 14.36 17.11 28.49 26.10 17.17 8.73 6.30 
13.26 11.99 15.22 27.03 23.68 14.41 7.01 4.46 
0.79 0.99 0.47 “0.07 �0.18 ‘0.45 1.48 1.14 
3.71 3.70 3.73 2.78 3.09 4.91 4.14 3.12 
1.22 1.38 0.97 �0.46 1.42 1.19 1.18 1.75 
9.49 8.55 10.94 +0.34 “0.53 2.90 13.66 21.44 
3.87 3.23 4.87 ‘0.15 �0.36 1.09 5.28 9.08 
3.33 3.42 3.19 �0.1 1 *0.12 1.32 5.46 6.59 
2.16 1.79 2.72 “0.08 *0.05 ‘0.38 2.78 5.52 
16.29 17.06 15.09 5.84 11.55 21.75 20.72 16.16 
8.51 8.35 8.74 4.47 6.42 9.89 10.33 9.10 
2.41 2.62 2.10 �0.29 1.44 3.39 3.58 2.22 
3.68 4.05 3.12 0.70 2.25 4.76 4.98 4.09 
7.65 8.05 7.02 �0.56 1.59 4.62 11.67 13.81 
6.30 6.70 5.69 40.21 ‘0.93 3.85 9.63 11.69 
2.78 2.53 3.17 6.49 3.30 2.69 1.80 1.07 
3.84 3.58 4.24 4.01 3.10 3.46 3.28 4.98 
3.55 3.47 3.67 2.13 2.41 3.42 4.14 4.56 
8.22 9.98 5.48 1.93 9.76 9.37 10.44 8.52 
2.69 2.67 2.74 1.45 2.42 3.03 3.48 2.56 
3.49 2.94 4.34 14.50 2.52 0.81 0.99 1.28 
8.12 7.88 8.53 8.43 15.77 10.75 5.72 4.61 
1.70 1.40 2.15 1.77 ‘0.53 1.03 1.84 2.64 
3.57 4.67 1.86 0.75 6.57 4.87 2.95 3.66 
2.22 2.04 0.97 4.82 2.37 1.82 1.52 1.42 
1.47 1.49 1.45 1.03 1.47 1.64 1.84 1.25 













. Serums, toxoids, and vaccines. 
� Spasmolytic agents. 
There was no significant difference between the 
sexes in their respective utilization of drugs in the 
following therapeutic categories: 
. Autonomic drugs. 
. Blood formation and coagulation agents. 
. Expectorants and cough preparations. 
� Eye, ear, nose, and tlmoat preparations. 
� Gastrointestinal drugs. 
. Skin and mucous membrane preparations. 
Table 2 also shows the effect of advancing age on 
the utilization of the therapeutic categories. Figure 4 
graphically pictures this effect by tracing an age curve 
for the three, most mentioned, therapeutic categories. 
All three are age sensitive. The utilization curve for 
the anti-infective agents shows a steady descent with 
advancing years while the curve for cardiovascular 
drugs rises gradually till the 45th year, then steeply to 
a peak in the age group over 64. The utilization curve 
for central nervous system drugs shows its steepest 
ascent at ages 15-44 years, levels off for the rest of 
the middle years, and finally begins a gradual descent 
in the older years of life. 
Drug utilization: specific drugs 
The data user will note that–in its attempt to 
explore differences related to sex and age of the pa­
tient–this report has moved progressively in the 
direction of increasing specificity. The exploration 
ends with the descriptive data in table 3, which list in 
rank order the 10 drugs most frequently mentioned 
for each of the sex-age groups. (Inclusion of trade 
names is for identification only and does not imply 
endorsement by the Public Health Service or the 
United States Department of Health and Human 
Services.) 
The drugs are listed by entry name, that is, by the 
trade or generic name that the doctor recorded on the 
— Anti-infective agents 
.-...s Cardiovascular drugs 
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Under 15-24 25-44 45-64 65 years 
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Age of patient 
Figure 4. Utilization of three therapeutic categories of drugs by age of 
patient, based on percent of drug mentions within respective age 
groups: United States, 1980 
NAMCS visit record (figure 1). (Note: NAMCS re­
spondents were instructed to use the same entry 
name on the NAMCS visit record that they used on 
the patient’s medical recor~ and/or on any prescrip­
tion written.) 
A superscript following a listed drug indicates a 
drug family; a grouping of drugs whose members have 
the same core name and the same or a closely similar 
therapeutic effect. For example, the drug family 
Aristocortf includes the following members: Aris­
tocort, Aristocort A, Aristocort Forte, Aristocort HP, 















































































Table 3. Number of drug mentions and drug mention rate per 1,000 visits for the 10 drugs most frequently ordered or provided to patients in 
selected sex-age groupx United States, 1980 
Number Drug Number Drug 
Rank 






rate per Rank 
1,000 








thousands visits thousands visits 
Female patients under 15 years Male patients under 15 years 
polio vaccine . . . . . . . . . . . . . . . . . . 3,114 61.7 1 Polio vaccine . . . . . . . . . . . . . . . . . . . . . 3,067 52.1 
Diphtheria tetanus toxoid pertussis . . . . 3,028 60.0 2 Diphtheria tetanus toxoid pertussis . . . . 2,835 48.2 
Amoxicillin . . . . . . . . . . . . . . . . . . . . . . 1,906 37.7 3 Allergy relief, unspecified . . . . . . . . . . . . 2,511 42.7 
Tuberculin tine test . . . . . . . . . . . . . . . . 1,752 34.7 4 Amoxicillin . . . . . . . . . . . . . . . . . . . . . . 2,462 41.8 
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . 1,648 32.6 5 Dimetapp (brompheniramine, phenyl-
Peniciliinf . . . . . . . . . . . . . . . . . . . . . . . . 1,646 32.6 eplwine, phenylpropanolamine) . . . . . . 2,21,2 37.6 
Dimetapp (brompheniramine, phenyl- 6 Penicillinf . . . . . . . . . . . . . . . . . . . . . . . . 1,720 29.2 
ephrine, phenylpropanolamine) . . . . . . 1,471 29.1 7 Tuberculin tinetest . . . . . . . . . . . . . . . . 1,696 28.8 
8 Allergy relief, unspecified . . . . . . . . . . . . 1,325 26.2 8 Ampicillin . . . . . . . . . . . . . . . . . . . . . . . 1,635 27.8 
9 Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . 1,096 21.7 9 Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . 1,324 22.5 
10 E.E.S . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,041 20.6 10 Amoxil(amoxicillin) . . . . . . . . . . . . . . . 1,230 20.9 
Female patients 15-24 years Male patients 15-24 years 
1 Tetracyclinef . . . . . . . . . . . . . . . . . . . . . 1,642 29.9 Tetracyclinef . . . . . . . . . . . . . . . . . . . . . 1,394 52.2 
2 Ampicillin . . . . . . . . . . . . . . . . . . . . . . . 1,291 23.5 Penicillinf . . . . . . . . . . . . . . . . . . . . . . . . 828 31.0 
3 Penicillin . . . . . . . . . . . . . . . . . . . . . . . . 1,183 21.6 Allergy relief, unspecified . . . . . . . . . . . . 801 30.0 
4 Ortho-Novum (rrorethindrone, Cieocinf (clindamycin) . . . . . . . . . . . 773 29.0 
mestranol) . . . . . . . . . . . . . . . . . . . . . . 1,000 18.2 Ampicillin . . . . . . . . . . . . . . . . . . . . . . . 664 24.9 
5 Prenatal vitamins . . . . . . . . . . . . . . . . . . 972 17.7 Aspirin . . . . . . . . . . . . . . . . . . . . . . . .. . . 473 17.7 
6 Cleocinf (clindamycin) . . . . . . . . . . . . . . 969 17.7 Minocin (minocyciine) . . . . . . . . . . . . . . *376 *14.1 
7 Lo/Ovral (norgestrel, ethinyl, Tetanustoxoid . . . . . . . . . . . . . . . . . . . . *326 *12.2 
estradiol) . . . . . . . . . . . . . . . . . . . . . . . 796 14.5 Erythromycin . . . . . . . . . . . . . . . . . . . . . ’313 *11.7 
8 Allergy relief, unspecified . . . . . . . . . . . . 725 13.2 Desquam-Xf (benzoyl peroxide, 
9 Materna (multivitamins prenatal) . . . . . . 692 12.6 disodium edetate, etc.) . . . . . . . . . . . . . *299 *11.2 
10 Monistatf (miconazole) . . . . . . . . . . . . . 682 12.4 
Female patients 25-44 years Male patients 2544 years 
Tetracyclinef . . . . . . . . . . . . . . . . . . . . . 1,961 18.9 Allergy relief, unspecified . . . . . . . . . . . . 1,062 20.8 
Allergy relief, unspecified . . . . . . . . . . . . 1,579 15.2 Penicillin . . . . . . . . . . . . . . . . . . . . . . . . 1,022 20.0 
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . 1,565 15.1 Tetracyclinef . . . . . . . . . . . . . . . . . . . . . 987 19.3 
Penicillin . . . . . . . . . . . . . . . . . . . . . . . . 1,370 13.2 Ampicillin . . . . . . . . . . . . . . . . . . . . . . . 971 19.0 
Lasix(furosemide) . . . . . . . . . . . . . . . . . 1,209 11.7 Valium (diazepam) . . . . . . . . . . . . . . 644 12.6 
Prenatal vitamins . . . . . . . . . . . . . . . . . . 1,109 10.7 Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . 607 11.9 
Vitamin B-12 . . . . . . . . . . . . . . . . . . . . . 1,095 10.6 Erythromycin . . . . . . . . . . . . . . . . . . . . . 585 11.4 
Valium (diazepam) . . . . . . . . . . . . . . . . . 1,091 10.5 Keflex (cephalexin) . . . . . . . . . . . . . . . . 571 11.2 
Monistatf (miconazole) . . . . . . . . . . . . . 1,069 10.3 Actifed (tripolidine, pseudoephedrine) . . 552 10.8 
Chorionic gonadotropin . . . . . . . . . . . . . 1,001 9.7 Darvocet-N (acetaminophen, pro-
poxyphene napsyIate) . . . . . . . . . . . . . 549 10.7 
Female patients 45-64 years Male patients 45-64 years 
Inderal (propranoloi) . . . . . . . . . . . . . . . 1,904 24.9 Inderal (propranolol) . . . . . . . . . . . . . . . 2,295 43.1 
Lasix(furosemide) . . . . . . . . . . . . . . . . . 1,804 23.6 Dyazide (triamterene) . . . . . . . . . . . . . . 1,258 23.6 
Premarin (conjugated estrogens) . . . . . . . 1,704 22.3 Lasix(furosernide) . . . . . . . . . . . . . . . . . 1,157 21.7 
Dyazide (triamterene) . . . . . . . . . . . . . . 1,675 21.9 Valium (diazepam) . . . . . . . . . . . . . . 1,105 20.7 
Motrin (ibuprofen) . . . . . . . . . . . . . . . . . 1,652 21.6 Hydrochlorothiazide . . . . . . . . . . . . . 1,000 18.8 
Valium (diazepam) . . . . . . . . . . . . . . . . . 1,594 20.9 Insulin. . . . . . . . . . . . . . . . . . . . . . . . . . 950 17.B 
Hydrochlorothiazide . . . . . . . . . . . . . . . 1,548 20.3 Lanoxin(digoxin) . . . . . . . . . . . . . . . . . 947 17.8 
Vitamin B-12 . . . . . . . . . . . . . . . . . . . . . 1,348 17.6 Tagamet (cimetidine) . . . . . . . . . . . . . . . 936 17.6 
Aldomet (methyldopa) . . . . . . . . . . . . . . 1,295 17.0 Lopressor (metoprolol) . . . . . . . . . . . . . 877 16.5 
Thyroid . . . . . . . . . . . . . . . . . . . . . . . . . 1,246 16.3 Hydrodiuril (hydrochlorothiazide) . . . . . 871 16.4 
Female patients 65 years and over Male patients 65 years and over 
Lanoxin (digoxin) . . . . . . . . . . . . . . . . . 3,089 50.8 Lasix (furosemide) . . . . . . . . . . . . . . . . . 2,247 56.6 
Lasix(f,~rosemide) . . . . . . . . . . . . . . . . . 2,931 48.2 Lanoxin (digoxin) . . . . . . . . . . . . . . . . . 2,078 52.3 
Dyazide (triamterene) . . . . . . . . . . . . . . 2,613 43.0 Inderal (propranolol) . . . . . . . . . . . . . . . 1,609 40.5 
Irrderal (propranolol) . . . . . . . . . . . . . . . 2,576 42.4 Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . 1,512 38.1 
Aldomet (methyldopa) . . . . . . . . . . . . . . 2,067 34.0 Isordil (isosorbide) . . . . . . . . . . . . . . . . . 1,143 28.8 
Vitamin B-1 2 . . . . . . . . . . . . . . . . . . . . . 1,987 32.7 Dyazide (triamterene) . . . . . . . . . . . . . . 956 24.1 
Digoxin . . . . . . . . . . . . . . . . . . . . . . . . . 1,793 29.5 Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . 765 19.3 
Motrin (ibuprofen) . . . . . . . . . . . . . . . . . 1,467 24.1 Hydrochlorothiazide . . . . . . . . . . . . . . . 761 19.2 
Insulin . . . . . . . . . . . . . . . . . . . . . . . . . . 1,382 22.7 Hydrodiuril (hydrochlorothiazide) . . . . . 742 IB.7 
Hydrochlorothiazide . . . . . . . . . . . . . . . 1,340 22.0 Prednisone . . . . . . . . . . . . . . . . . . . . . . . 715 18.0 
Superscriptf denotes drug family. 
A , 
Symbols 
. . . Data not available 
. . . Category not applicable 
Quantity zero 
0.0	 Quantity more than zero butless than 
0.05 
z	 Quantity more than zero but less than 
500 where numbers are rounded to 
thousands 
* Figure does not meet standards of 
reliability or precision (more than 
30 percent relative standard error) 




Source of data and sample design 
The estimates presented in this report are based 
on data collected during 1980 by the National Center 
for Health Statistics by means of the National 
Ambulatory Medical Care Survey. The target universe 
of NAMCS comprises office visits made by ambula­
tory patients to non-Federal physicians who are 
principally engaged in office-based, patient care prac­
tice. Visits to physicians practicing in Alaska and 
Hawaii are excluded from the range of NAMCS, as are 
visits to physicians who specialize in anesthesiology, 
pathology, and radiology. 
NAMCS uses a multistage probability sample de-
sign that involves a step-wise sampling ofi primary 
sampling units (PSU’S), physicians’ practices within 
PSU’S, and patient visits within physicians’ practices. 
For 1980 a sample of 2,959 physicians was selected 
from master fdes maintained by the American Medi­
cal Association and the American Osteopathic Asso­
ciation. The physician response rate was 77.2 percent. 
Sampled physicians were asked to complete Patient 
Records (figure 1) for a systematic random sample of 
office visits made during a randomly assigned weekly 
reporting period. Telephone contacts were excluded. 
During 1980, responding physicians completed 
46,081 Patient Records, on which they recorded 
51,372 drug mentions. Characteristics of the physi­
cian’s practice, such as primary specialty and type of 
practice, were obtained during an induction interview. 
The National Opinion Research Center, under con-
tract to the National Center for Health Statistics, was 
responsible for the survey’s field operations. 
For a more detailed discussion of the limitations, 
qualifications, and definitions of the data collected 
by NAMCS, see Vital and Health Statistics, Series 13, 
Number 44. 
Sampling errors and rounding of numbers 
The standard error is a measure of the sampling 
variability that occurs by chance because only a sam­
ple, rather than an entire universe, is surveyed. The 
relative standard error of the estimate is obtained by 
dividing the standard error by the estimate itself and 
is expressed as a percent of the estimate. Tables I 
and II apply these measurements to office visits; 
Tables III and IV apply them to drug mentions. 
Estimates have been rounded to the nearest thou-
sand. For this reason detailed figures within tables do 
not always add to totals. Rates and percents were cal­
culated from original, unrounded figures and will not 
necessarily agree precisely with rates or percents 
calculated from rounded data. 
Table 1. Approximate relative standard errors of estimated number 
of office visits based on all physician specialties NAMCS, 1980 
Relative 
Estimated number of office standard 
visits in thousands error in 
percent 
500 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27.3 
1,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19.5 
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.1 
5,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9,4 
10,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.3 
20,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.9 
50,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.9 
100,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.5 
550,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.1 
Example of use of table: An aggregate of 75,000,000 visi~ hes a 
relative standard arror of 4.7 percent or a standard arror of 3,525,000 
visie (4.7 percent of 75,000,000). 
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Table Il. Approximate standard errors o! percents of estimated number of office visits based on all physician specialties: NAMCS, 1980 
Base of percent 
Estimated percent 
(number of office visits in thousands) 
1 or 99 5 or 95 100r90 20 or 80 30 or 70 50 
Standard error in percent 
500 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.7 5.9 8.1 10.8 12.4 13.5 
1,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.9 4.2 5.7 7.6 8.7 9,5 
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.3 2.9 4.0 5.4 6.2 6.7 
5,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.8 1.9 2.6 3.4 3.9 4.3 
10,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.6 1.3 1,8 2.4 2.8 3.0 
20,000 . . . . . . . . . . . . . . . . . . . . . . . . ! . . . . . . . . . . . 0.4 0.9 1,3 1.7 2.0 2.1 
50,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.3 0.6 0.8 1.1 1.2 1.3 
100,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.2 0.4 0.6 0.8 0.9 1.0 
500,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.1 0.2 0.3 0<3 0.4 0.4 
Examole of use of table: An estimate of 30 percent based on an aggregata of 15,000,000 visits has a standard error of 2.4 nercent. or a relative 
stendard error of Spercent (2.4 percent +30 percent). 
Table Ill. Approximate reletive standard errors of estimated number 
ofdrugmentions based onall physician specialties: NAMCS,1980 
Relative 
Estimated number of drug mentions standard 
in thousands error in 
percent 
1,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27.3 
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19.7 
5,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.2 
10,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.1 
20,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.2 
50,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.8 
100,000. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.2 
300,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.8 
650.000 . . . . . . . . . . . . . . . . . . . . . . .. s........ 5.7 
Exampla of usa of table: An aggregate estimate of 75,000,000 drug 
mantions has arelative standard error of 6.5parcent ora standard error 
of4,875,000 mentions (6.5 percent of 75,000,000). 
Definitions 
An ambulatory patient is an individual seeking 
personal health service who is neither bedridden nor 
currently admitted to any health care institution on 
thepremises. 
A physician eligible forNAiVCS is a duly licensed 
doctor ofmedicine or osteopathy currently in office-
based practice whose primary job is caring forambu­
latory patients. Excluded from NAMCS are: physi­
cians who are hospital based; physicians who 
specialize in anesthesiology, pathology, or radiology; 
physicians who are Federally employed; physicians 
who treat only institutionalized patients; physicians 
employed full time by an institution; and physicians 
who spendno time seeing ambulatory patients. 
An office is a place that the physician identifies 
as alocation forhis ambulatory practice. Responsibil­
ity overtime for patient care and professional services 
rendered there generally resides with the individual 
physician rather than aninstitution. 
A visit is a direct personal exchange between an 
ambulatory patient andaphysician ora staff member 
working under the physician’s supervision, for the 
purpose of seeking care or rendering health services. 
A drug mention is the physician’s entry of a phar­
maceutical agent ordered or provided–by any route 
of administration-for prevention, diagnosis, or treat­
ment. Generic as well as brand-name drugs are in­
cluded, as are nonprescription as well as prescription 
drugs. Along with all new drugs, the physician also 
records continued medications, if the patient was 
specifically instructed during the visit to continue the 
medication. 
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Table IV. Approximate standard errors of percents of estimated numkers of drug mentions based on all physician specialties NAMCS, 1980€
Base of percent Estimated percent 
(number of drug mentions in thousands) 
1 or 99 5 or 95 10 or 90 20 or 80 30 or 70 50 
1,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.7 5.8 
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.9 4.1 
5,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.2 2.6 
20,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.6 1.3 
100,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.3 0.6 
600,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.1 0.2 
Standard error in percentage points€
8.0 10.7 12.2 13.3€
5.7 7.6 8.7 9.4€
3.6 4.8 5.5 6.0€
1.8 2.4 2.7 3.0€
0.8 1.1 1.2 1.3€
0.3 0.4 0.5 0.5€
Exampla of use of table: An astimata of 30 parcent based on an aggregate of 12,500,000 drug mentions has a atanderd error of 4.1 percant or a 
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